← Back to Search

Other

Standardized Care for Liver Cirrhosis (CCAB Trial)

N/A
Recruiting
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults (great than 18 years of age) with a clinical diagnosis of cirrhosis (confirmed by compatible radiology, histology or fibroscan)
Be older than 18 years old
Must not have
Adult patients who do not have cirrhosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 year, 2 year
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether the CCAB improves patient outcomes.

Who is the study for?
This trial is for adults over 18 with a clinical diagnosis of cirrhosis, confirmed by radiology, histology or fibroscan, who are admitted to a study hospital site. It's not open to those without cirrhosis.
What is being tested?
The CCAB program aims to improve care quality and reduce hospital visits for liver cirrhosis patients through evidence-based management practices including support for alcohol use, frailty assessment, advance care planning and structured transitions from home to hospital and back.
What are the potential side effects?
Since the intervention involves implementing best practice guidelines rather than medication, traditional side effects aren't expected. However, changes in care may lead to adjustments in patient experience.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 and have been diagnosed with cirrhosis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have cirrhosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 year, 2 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 year, 2 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cumulative hospital length of stay (LOS) per patient year
Secondary study objectives
Disease severity
Emergency Department (ED) Visit Rate
Hospital Readmission Rate
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Use of a standardized cirrhosis order set.
Group II: ControlActive Control1 Intervention
Current practice at baseline, routine cirrhosis care.
Group III: Intervention + EMRActive Control1 Intervention
Use of a standardized cirrhosis order set embedded within an electronic medical record.

Find a Location

Who is running the clinical trial?

Alberta Innovates Health SolutionsOTHER
53 Previous Clinical Trials
90,168 Total Patients Enrolled
Alberta Health servicesOTHER
163 Previous Clinical Trials
648,683 Total Patients Enrolled
University of AlbertaLead Sponsor
937 Previous Clinical Trials
429,849 Total Patients Enrolled
9 Trials studying Liver Cirrhosis
2,151 Patients Enrolled for Liver Cirrhosis

Media Library

Evidence-based standardized Cirrhosis order set (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04149223 — N/A
Liver Cirrhosis Research Study Groups: Intervention, Control, Intervention + EMR
Liver Cirrhosis Clinical Trial 2023: Evidence-based standardized Cirrhosis order set Highlights & Side Effects. Trial Name: NCT04149223 — N/A
Evidence-based standardized Cirrhosis order set (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04149223 — N/A
~381 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top